DownloadHi-Res Photo

Michael Girardi, MD, FAAD

Vice Chair for Faculty Development and Scientific Innovation. Evans Professor of Dermatology; Director, Residency Program, Dermatology; Co-Director, T32 Research Fellowship Program, Dermatology

Contact Information

Lab
203.785.6564
Email
michael.girardi@yale.edu

Mailing Address

Dermatology
PO Box 208059, 333 Cedar Street
New Haven, CT 06520-8059
United States

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research & Publications
Biography
News

Research Summary

Dr. Girardi’s principal research focus as a faculty member has been to investigate the relationship between the immune system and cancer from two complimentary perspectives: as a laboratory / translational investigator, and as a clinical scholar. He has published in high impact journals (Science, Nature, New England Journal, Nature Immunology, Journal of Experimental Medicine, Proceedings of the National Academy of Sciences). In addition, he has developed an internationally recognized clinical expertise in several areas including cutaneous T cell lymphoma (CTCL), squamous cell carcinoma (SCC), and the immunodulatory treatment extracorporeal photochemotherapy (ECP). His scientific and clinical scholarly accomplishments have been recently recognized by his elected membership into the American Society for Clinical Investigation. His laboratory has made several advances in our understanding of the immunoregulation of carcinogenesis.

Specialized Terms: Cancer; Carcinogenesis; Cellular Immunology; Chemotherapy; Dermatology; DNA; Immunobiology; Immunology; Lymphoma; Receptors; Tumor Immunology

Extensive Research Description

Dr. Girardi’s current research projects include:

1. Identification of genetic drivers of CTCL. Dr. Girardi's lab provided the most comprehensive description of gene copy number alterations in CTCL [J Invest Dermatol, 2012], and then more fully elucidated the genetic drivers of CTCL [Nature Genetics, 2015]. This is now part of an integrated data resource [J Invest Dermatol, 2018]. Dr. Girardi's lab also developed the first cytogenetics panel for CTCL [J Invest Dermatol, 2017], now implemented by Yale Clinical Genetics, and identified precancerous cells in the circulation of CTCL patients using dual single-cell RNA/TCR seq [Blood Adv., 2023].

A. Lin WM, Lewis JM, Filler RB…Dummer T, Berger CL, Edelson RL, Girardi M. (2012). Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. J Invest Dermatol. 132(1):188-197. PMCID: PMC3841973

B. Choi J, Goh G, Walradt T…Girardi M & Lifton RP. (2015). Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 47(9):1011-9. PMCID: PMC4552614

C. Weed J, Gibson J, Lewis J, Carlson K, Foss F, Choi J, Li P, Girardi M. (2017). FISH panel for leukemic CTCL. J Invest Dermatol. 137(3):751-753. PMCID: PMC5419071

D. Ren J, Qu R, Rahman NT, Lewis JM, King ALO, Liao X, Mirza FN, Carlson KR, Huang Y, Gigante S, Evans B, Rajendran BK, Xu S, Wang G, Foss FM, Damsky W, Kluger Y, Krishnaswamy S, Girardi M. Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations. Blood Adv. 2023;7(3):445-457. doi: 10.1182/bloodadvances.2022008168. PMID: 35947128

2. Innovation for the management and treatment of CTCL. Dr. Girardi's lab developed modified criteria for use of Vbeta panel flow cytometry diagnosis of CTCL [J Amer Acad Dermatol, 2016] now implemented by YNHH Flow Cytometry. His lab characterized BCL2 [Blood, 2015], BET [Oncotarget, 2018], JAK [Blood Adv, 2020], and proteosome [J Invest Dermatol, 2023] targeting activity against CTCL, and their defined their synergy with established anti-CTCL agents. Dr. Girardi's lab's current collaborative research efforts in this area include drug design using synergistic chemistry where single agents are developed with dual targeting and synergistic drug combinations for the treatment of advanced stage CTCL.

A. Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. (2017). Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood. 130(19):2073-2083. PMCID: PMC5680613

B. Kim SR, Lewis JM, Cyrenne BM, Mirza FN, Carlson KR, Foss FM, Girardi M. (2018). BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Oncotarget. 9(49):29193-29207. doi: 10.18632/oncotarget.25670. PMCID: PMC6044378

C. Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. (2020) JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Adv. 4(10):2213-2226. PMCID: PMC7252559

D. Xu S, Ren J, Lewis JM, Carlson KR, Girardi M. Proteasome inhibitors interact synergistically with BCL2, histone deacetylase, BET, and Jak inhibitors against cutaneous T-cell lymphoma cells. J Invest Dermatol. 2023 Jan 13:S0022-202X(23)00011-8. doi: 10.1016/j.jid.2022.12.017. Online ahead of print. PMID: 36642402

3. Novel strategies for the prevention and treatment of skin cancer. In collaboration with W. M. Saltzman, PhD, Dr. Girardi's lab developed a novel drug delivery system of bioadhesive biodegradable nanoparticles to prevent skin cancer [Nature Materials, 2015; Bioeng Transl Med, 2018], and improve the local delivery of chemotherapeutic and immunostimulatory agents to skin cancers [PNAS, 2021]. His current collaborative research efforts in this area include novel site-directed therapeutics for BCC and peritoneal carcinomatosis / ovarian cancer (with W.M. Saltzman, via Yale start-up Stradefy Biosciences).

A. Deng Y, Ediriwickrema A, Yang F, Lewis J, Girardi M & Saltzman WM. (2015). A sunblock based on bioadhesive nanoparticles. Nat Mater.14(12):1278-85. doi: 10.1038/nmat4422. Epub 2015 Sep 28. PMCID: PMC4654636

B. Suh HW, Lewis J, Fong L, Ramseier JY, Carlson K, Peng ZH, Yin ES, Saltzman WM & Girardi M. (2018). Biodegradable bioadhesive nanoparticle incorporation of broad-spectrum organic sunscreen agents. Bioeng Transl Med. 4(1):129-140. doi: 10.1002/btm2.10092. PMCID: PMC6336670

C. Hu JK, Suh H-W, Qureshi M, Lewis JM, Yaquoob S, Moscato ZM, Griff S, Lee AK, Yin ES, Saltzman WM & Girardi M. (2021). Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles. Proc Natl Acad Sci U S A. doi: 10.1073/pnas.2020575118. PMID: 33526595

D. Mai Y, Ouyang Y, Yu M, Qin Y, Girardi M, Saltzman WM, …Deng Y. Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis. J Control Release. 2022 Jul 12;349:354-366. doi: 10.1016/j.jconrel.2022.07.006. PMID: 35817278

4. Elucidation of Langerhans cells (LC) role in skin homeostasis and carcinogenesis. Dr. Girardi's lab defined major roles for local immune cells in the regulation of the cutaneous stress response fundamental to carcinogenesis [Nat Immunol, 2006]. Dr. Girardi's lab established a paradigm for resident immune influences on mutagenesis within epithelial tissues [Science, 2012], while revealing that LC exert major influences in facilitating mutagenesis and tumor promotion [J Invest Dermatol, 2015; PNAS, 2021]. Dr. Girardi's current collaborative research efforts in this area include novel strategies for the inhibition of tumor promotion using topical RORgt inhibitors and miRNA target-based oligonucleotides (with Jeff Bender, MD, Yale Immunobiology).

A. Strid J, Roberts SJ, Filler RB, Lewis JM, Kwon, BY, Schpero W, Kaplan DH, Hayday AC, Girardi M. (2008). Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat Immunol. Feb;9(2):146-154. doi: 10.1038/ni1556. PMID: 18176566

B. Modi BG, Neustadter J, Binda E, Lewis J, Filler RB, Roberts SJ, Kwong BY, Reddy S, Overton JD, Galan A, Tigelaar RE, Cai L, Fu P, Shlomchik M, Kaplan DH, Hayday A, Girardi M. (2012). Langerhans cells facilitate epithelial DNA damage and squamous cell carcinoma. Science. 335(6064):104-108. PMCID: PMC3753811

C. Lewis JM, Bürgler CD, Fraser JA, Liao H, Golubets K, Kucher CL, Zhao PY, Filler RB, Tigelaar RE, Girardi M. (2015). Mechanisms of chemical cooperative carcinogenesis by epidermal Langerhans cells. J Invest Dermatol. 135(5):1405-1414. PMCID: PMC4364923

D. Lewis JM, Mirza FN, Xu S, Yumeen S, Turban JL, Galan A, Girardi M. (2021). Chronic UV radiation-induced RORγt+ IL-22-producing lymphoid cells are associated with mutant KC clonal expansion. Proc Natl Acad Sci U S A. Sep 14;118(37):e2016963118. doi: 10.1073/pnas.2016963118. PMID: 34504008

5. alpha-beta and gamma-delta T cell regulation of inflammation and tumor promotion. Dr. Girardi and colleagues were the first to demonstrate the critical contribution of gd T cells to the regulation of cutaneous malignancy [Science, 2001; J Exp Med, 2003a], while elucidating the differential contributions of gd and ab T cells [PNAS, 2007; J Exp Med, 2003b].

A. Girardi M, Oppenheim DE, Steel CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. (2001). Regulation of cutaneous malignancy by gd T cells. Science. 294(5542):605-609. doi: 10.1126/science.1063916. PMID: 11567106

B. Girardi M, Lewis J, Glusac E, Filler RB, Geng L, Hayday AC, Tigelaar RE. (2002). Resident skin-specific gamma/delta T cells provide local, nonredundant regulation of cutaneous inflammation. J Exp Med. 195(7):855-67. doi: 10.1084/jem.20012000. PMCID: PMC2193718

C. Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis JM, Tigelaar RE, Hayday AC. (2003). The distinct contributions of murine TCRgd+ and TCRab+ T cells to different stages of chemically induced skin cancer. J Exp Med. 198(5):747-755. PMCID: PMC2194182

D. Roberts SJ, Ng BY, Filler RB, Lewis J, Glusac EJ, Hayday AC, Tigelaar RE, Girardi M. (2007). Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci U S A. 104(16):6770-6775. PMCID: PMC1871860

Coauthors

Research Interests

Dermatology; DNA; Graft vs Host Disease; Immune System; Internship and Residency; Skin Neoplasms; Lymphoma, T-Cell, Cutaneous; Carcinogenesis

Research Images

Slide1

Selected Publications

FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical OutcomesAvery J, Kim R, Cheng W, Foss F, Girardi M. FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes. JID Innovations 2023, 3: 100212. PMID: 37674691, PMCID: PMC10477749, DOI: 10.1016/j.xjidi.2023.100212.
1091 Improving the anti-tumor efficacy of immunomodulator MPLA via biodegradable nanoparticle deliveryChang J, Shin K, Lewis J, Suh H, Bosenberg M, Saltzman W, Girardi M. 1091 Improving the anti-tumor efficacy of immunomodulator MPLA via biodegradable nanoparticle delivery. Journal Of Investigative Dermatology 2023, 143: s187. DOI: 10.1016/j.jid.2023.03.1103.
Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and TreatmentChang J, Yu B, Saltzman W, Girardi M. Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment. JID Innovations 2023, 3: 100197. PMID: 37205301, PMCID: PMC10186617, DOI: 10.1016/j.xjidi.2023.100197.
A case of bullous lesions in cutaneous T-cell lymphomaXu S, Weiss E, Singh K, Damsky W, Girardi M. A case of bullous lesions in cutaneous T-cell lymphoma. JAAD Case Reports 2023, 35: 90-93. PMID: 37223111, PMCID: PMC10201206, DOI: 10.1016/j.jdcr.2023.02.026.
Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populationsRen J, Qu R, Rahman N, Lewis J, King A, Liao X, Mirza F, Carlson K, Huang Y, Gigante S, Evans B, Rajendran B, Xu S, Wang G, Foss F, Damsky W, Kluger Y, Krishnaswamy S, Girardi M. Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations. Blood Advances 2023, 7: 445-457. PMID: 35947128, PMCID: PMC9979716, DOI: 10.1182/bloodadvances.2022008168.
A rare presentation of cutaneous T-cell lymphoma mimicking morpheaYu B, Kim R, Roy S, Girardi M. A rare presentation of cutaneous T-cell lymphoma mimicking morphea. JAAD Case Reports 2023, 33: 59-61. PMID: 36860808, PMCID: PMC9969200, DOI: 10.1016/j.jdcr.2023.01.007.
Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma CellsXu S, Ren J, Lewis J, Carlson K, Girardi M. Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells. Journal Of Investigative Dermatology 2023, 143: 1322-1325.e3. PMID: 36642402, DOI: 10.1016/j.jid.2022.12.017.
Treatment of toxic epidermal necrolysis and concurrent COVID-19-associated hyperinflammatory syndrome with systemic corticosteroids and etanerceptChoi R, Garritano J, Laird M, Johnston M, Tkachenko E, Damsky W, Little AJ, McNiff J, Girardi M, Nelson CA. Treatment of toxic epidermal necrolysis and concurrent COVID-19-associated hyperinflammatory syndrome with systemic corticosteroids and etanercept. JAAD Case Reports 2022, 29: 139-141. PMID: 36160836, PMCID: PMC9485430, DOI: 10.1016/j.jdcr.2022.09.009.
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides). JAMA Dermatology 2022, 158: 1031-1039. PMID: 35857290, PMCID: PMC9301595, DOI: 10.1001/jamadermatol.2022.2749.
Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable AnalysisKing ALO, Lee V, Mirza FN, Jairam V, Yang DX, Yu JB, Park HS, Girardi M, Wilson LD, An Y, Wilson L. Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis. Cureus 2022, 14: e28043. PMID: 36120198, PMCID: PMC9474264, DOI: 10.7759/cureus.28043.
Comment on “Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab”Cohen JM, Damsky W, Girardi M. Comment on “Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab”. Journal Of The American Academy Of Dermatology 2022, 87: e241-e242. PMID: 35933070, DOI: 10.1016/j.jaad.2022.05.069.
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTCOlsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022, 140: 419-437. PMID: 34758074, PMCID: PMC9353153, DOI: 10.1182/blood.2021012057.
LB998 Lymph node delivery of immunstimulatory agent monophosphoryl lipid A via bioadhesive nanoparticles in the treatment of cutaneous melanomaChang J, Shin K, Lewis J, Suh H, Bosenberg M, Saltzman W, Girardi M. LB998 Lymph node delivery of immunstimulatory agent monophosphoryl lipid A via bioadhesive nanoparticles in the treatment of cutaneous melanoma. Journal Of Investigative Dermatology 2022, 142: b29. DOI: 10.1016/j.jid.2022.05.1024.
831 Proteasome inhibitor functional profiling in CTCLXu S, Lewis J, King A, Umlauf S, Carlson K, Foss F, Girardi M. 831 Proteasome inhibitor functional profiling in CTCL. Journal Of Investigative Dermatology 2022, 142: s144. DOI: 10.1016/j.jid.2022.05.845.
580 Biodegradable bioadhesive nanoparticle delivery of chemotherapy for the treatment of cutaneous malignanciesChang J, Suh H, Lewis J, Bosenberg M, Saltzman W, Girardi M. 580 Biodegradable bioadhesive nanoparticle delivery of chemotherapy for the treatment of cutaneous malignancies. Journal Of Investigative Dermatology 2022, 142: s99. DOI: 10.1016/j.jid.2022.05.589.
Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasisMai Y, Ouyang Y, Yu M, Qin Y, Girardi M, Saltzman WM, Cocco E, Zhao C, Yu L, Jia Y, Xiao L, Dou L, Deng W, Liu Y, Xie J, Deng Y. Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis. Journal Of Controlled Release 2022, 349: 354-366. PMID: 35817278, DOI: 10.1016/j.jconrel.2022.07.006.
Treatment at high-volume facilities is associated with improved overall survival for patients with cutaneous B-cell lymphomaCheraghlou S, Ugwu N, Girardi M. Treatment at high-volume facilities is associated with improved overall survival for patients with cutaneous B-cell lymphoma. Journal Of The American Academy Of Dermatology 2022, 88: 203-205. PMID: 35476920, DOI: 10.1016/j.jaad.2022.04.032.
Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell LymphomaKim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, Angello JT, Bailey WL, Geskin LJ. Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal Of Clinical Dermatology 2022, 23: 425-425. PMID: 35292936, PMCID: PMC9172872, DOI: 10.1007/s40257-022-00676-1.
Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous MelanomaCheraghlou S, Ugwu N, Girardi M. Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma. JAMA Dermatology 2022, 158: 51-58. PMID: 34878492, PMCID: PMC8655663, DOI: 10.1001/jamadermatol.2021.4812.
Malignant T Cell Activation by a Bacillus Species Isolated from Cutaneous T-Cell Lymphoma LesionsDehner CA, Ruff WE, Greiling T, Pereira MS, Redanz S, McNiff J, Girardi M, Kriegel MA. Malignant T Cell Activation by a Bacillus Species Isolated from Cutaneous T-Cell Lymphoma Lesions. JID Innovations 2021, 2: 100084. PMID: 35199089, PMCID: PMC8844718, DOI: 10.1016/j.xjidi.2021.100084.
Response to Extracorporeal Photopheresis in Patients with Cutaneous T-Cell Lymphoma: A Retrospective Medical Chart ReviewGirardi M, Johnson A, Carlson K, Huang X, Corman S, Edmundson P, Kale H, Rusibamayila N, Foss F. Response to Extracorporeal Photopheresis in Patients with Cutaneous T-Cell Lymphoma: A Retrospective Medical Chart Review. Blood 2021, 138: 1405. DOI: 10.1182/blood-2021-151116.
Chronic UV radiation–induced RORγt+ IL-22–producing lymphoid cells are associated with mutant KC clonal expansionLewis JM, Monico PF, Mirza FN, Xu S, Yumeen S, Turban JL, Galan A, Girardi M. Chronic UV radiation–induced RORγt+ IL-22–producing lymphoid cells are associated with mutant KC clonal expansion. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2016963118. PMID: 34504008, PMCID: PMC8449378, DOI: 10.1073/pnas.2016963118.
Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro ScreeningsKing ALO, Mirza FN, Lewis JM, Umlauf S, Surovtseva Y, Carlson KR, Foss FM, Girardi M. Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings. Journal Of Investigative Dermatology 2021, 142: 254-257. PMID: 34293349, DOI: 10.1016/j.jid.2021.04.035.
A machine‐learning modified CART algorithm informs Merkel cell carcinoma prognosisCheraghlou S, Sadda P, Agogo GO, Girardi M. A machine‐learning modified CART algorithm informs Merkel cell carcinoma prognosis. Australasian Journal Of Dermatology 2021, 62: 323-330. PMID: 34028790, DOI: 10.1111/ajd.13624.
672 JAK inhibitor functional profiling in CTCLKing A, Mirza F, Lewis J, Yumeen S, Kim S, Carlson K, Foss F, Girardi M. 672 JAK inhibitor functional profiling in CTCL. Journal Of Investigative Dermatology 2021, 141: s117. DOI: 10.1016/j.jid.2021.02.702.
245 Factors associated with in-hospital mortality in mycosis fungoides patientsKing A, Lee V, Mirza F, Jairam V, Yu J, Park H, Girardi M, Wilson L, An Y. 245 Factors associated with in-hospital mortality in mycosis fungoides patients. Journal Of Investigative Dermatology 2021, 141: s44. DOI: 10.1016/j.jid.2021.02.267.
Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive MelanomaCheraghlou S, Christensen SR, Leffell DJ, Girardi M. Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma. JAMA Dermatology 2021, 157: 531-539. PMID: 33787836, PMCID: PMC8014201, DOI: 10.1001/jamadermatol.2021.0023.
305 A machine-learning modified CART algorithm informs Merkel Cell Carcinoma prognosisCheraghlou S, Sadda P, Agogo G, Girardi M. 305 A machine-learning modified CART algorithm informs Merkel Cell Carcinoma prognosis. Journal Of Investigative Dermatology 2021, 141: s54. DOI: 10.1016/j.jid.2021.02.327.
Necrotic papulonodules on the legsZhou A, Damsky W, Girardi M, Foss FM, Vesely MD. Necrotic papulonodules on the legs. JAAD Case Reports 2021, 11: 10-12. PMID: 33898676, PMCID: PMC8056172, DOI: 10.1016/j.jdcr.2021.03.012.
The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell LymphomaKim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, Angello JT, Bailey WL, Geskin LJ. The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal Of Clinical Dermatology 2021, 22: 407-414. PMID: 33656660, PMCID: PMC8068681, DOI: 10.1007/s40257-021-00591-x.
Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticlesHu JK, Suh HW, Qureshi M, Lewis JM, Yaqoob S, Moscato ZM, Griff S, Lee AK, Yin ES, Saltzman WM, Girardi M. Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2020575118. PMID: 33526595, PMCID: PMC7896333, DOI: 10.1073/pnas.2020575118.
B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphomaKing ALO, Mirza FN, Lewis JM, Carlson KR, Huntington S, Foss FM, Girardi M. B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma. JAAD Case Reports 2020, 8: 89-92. PMID: 33537387, PMCID: PMC7838714, DOI: 10.1016/j.jdcr.2020.12.025.
Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in DermatologyYumeen S, Mirza FN, Lewis JM, Girardi M. Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology. Journal Of Investigative Dermatology 2020, 140: 2319-2325.e1. PMID: 33222758, DOI: 10.1016/j.jid.2020.09.020.
Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell LymphomasLee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and NeckJacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.
Disparities in outcomes of CD8+ cutaneous T‐cell lymphoma by race and presenting lesion locationMirza F, Yumeen S, Girardi M. Disparities in outcomes of CD8+ cutaneous T‐cell lymphoma by race and presenting lesion location. British Journal Of Dermatology 2020, 184: 170-171. PMID: 32730673, DOI: 10.1111/bjd.19426.
Clarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects in Observational Research—ReplyCheraghlou S, Agogo GO, Girardi M. Clarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects in Observational Research—Reply. JAMA Dermatology 2020, 156: 1029-1029. PMID: 32520348, DOI: 10.1001/jamadermatol.2020.0543.
Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomasIsufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020, 61: 2955-2961. PMID: 32643494, DOI: 10.1080/10428194.2020.1790555.
854 Functional drug screening identifies candidate synergistic combinations for CTCL therapyYumeen S, Mirza F, Lewis J, King A, Kim S, Carlson K, Umlauf S, Surovtseva Y, Foss F, Girardi M. 854 Functional drug screening identifies candidate synergistic combinations for CTCL therapy. Journal Of Investigative Dermatology 2020, 140: s111. DOI: 10.1016/j.jid.2020.03.870.
110 RNA expression analysis in stage IVA-B cutaneous T-cell lymphoma to identify novel biomarkers of prognosis and diagnosisMirza F, Yumeen S, Lewis J, King A, Kim S, Carlson K, Foss F, Girardi M. 110 RNA expression analysis in stage IVA-B cutaneous T-cell lymphoma to identify novel biomarkers of prognosis and diagnosis. Journal Of Investigative Dermatology 2020, 140: s13. DOI: 10.1016/j.jid.2020.03.113.
578 Improved local drug delivery with bioadhesive nanoparticles in the treatment of skin cancerHu J, Suh H, Qureshi M, Lewis J, Saltzman W, Girardi M. 578 Improved local drug delivery with bioadhesive nanoparticles in the treatment of skin cancer. Journal Of Investigative Dermatology 2020, 140: s79. DOI: 10.1016/j.jid.2020.03.588.
Screening Novel Agent Combinations to Expedite CTCL Therapeutic DevelopmentMirza FN, Yumeen S, Lewis JM, King ALO, Kim S, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. Journal Of Investigative Dermatology 2020, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.
JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCLYumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.
CD8+ mycosis fungoides palmaris et plantaris with peripheral blood involvementYumeen S, Mirza FN, Lewis JM, Carlson KR, King B, Cowper S, Bunick CG, McNiff J, Girardi M. CD8+ mycosis fungoides palmaris et plantaris with peripheral blood involvement. JAAD Case Reports 2020, 6: 434-437. PMID: 32382639, PMCID: PMC7200192, DOI: 10.1016/j.jdcr.2020.02.025.
United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemicZic J, Ai W, Akilov O, Carter J, Duvic M, Foss F, Girardi M, Gru A, Kim E, Musiek A, Olsen E, Schieke S, Shinohara M, Zain J, Geskin L. United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. Journal Of The American Academy Of Dermatology 2020, 83: 703-704. PMID: 32305443, PMCID: PMC7161526, DOI: 10.1016/j.jaad.2020.04.049.
Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.Yumeen S, Girardi M. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma. The Yale Journal Of Biology And Medicine 2020, 93: 111-121. PMID: 32226341, PMCID: PMC7087059.
Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides.Hu JK, Carlson K, Girardi M. Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides. The Yale Journal Of Biology And Medicine 2020, 93: 41-44. PMID: 32226334, PMCID: PMC7087069.
Cutaneous Photoprotection: A Review of the Current Status and Evolving Strategies.Suozzi K, Turban J, Girardi M. Cutaneous Photoprotection: A Review of the Current Status and Evolving Strategies. The Yale Journal Of Biology And Medicine 2020, 93: 55-67. PMID: 32226337, PMCID: PMC7087054.
Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational studyKim EJ, Geskin L, Guitart J, Querfeld C, Girardi M, Musiek A, Mink DR, Williams MJ, Angello JT, Bailey WL. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study. Journal Of The American Academy Of Dermatology 2020, 83: 928-930. PMID: 32089294, DOI: 10.1016/j.jaad.2019.12.070.
Improving prognosis for early‐stage Merkel cell carcinoma: trends from 1981 to 2014Cheraghlou S, Agogo G, Girardi M. Improving prognosis for early‐stage Merkel cell carcinoma: trends from 1981 to 2014. British Journal Of Dermatology 2019, 182: 814-816. PMID: 31483861, DOI: 10.1111/bjd.18472.
Comparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive MelanomaCheraghlou S, Christensen SR, Agogo GO, Girardi M. Comparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive Melanoma. JAMA Dermatology 2019, 155: 1252-1259. PMID: 31553403, PMCID: PMC6764120, DOI: 10.1001/jamadermatol.2019.2890.
The impact of facility characteristics on Merkel cell carcinoma outcomes: A retrospective cohort studyCheraghlou S, Agogo GO, Girardi M. The impact of facility characteristics on Merkel cell carcinoma outcomes: A retrospective cohort study. Journal Of The American Academy Of Dermatology 2019, 89: 70-80. PMID: 31473294, DOI: 10.1016/j.jaad.2019.08.058.
Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell CarcinomaCheraghlou S, Agogo GO, Girardi M. Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma. JAMA Dermatology 2019, 155: 803-811. PMID: 30825411, PMCID: PMC6583886, DOI: 10.1001/jamadermatol.2019.0267.
Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*. Leukemia & Lymphoma 2019, 60: 2927-2930. PMID: 31119966, DOI: 10.1080/10428194.2019.1612061.
Novel Protocol for Generating Physiologic Immunogenic Dendritic CellsVentura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg M, Edelson R. Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. Journal Of Visualized Experiments 2019 DOI: 10.3791/59370-v.
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells.Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. Journal Of Visualized Experiments 2019 PMID: 31157760, DOI: 10.3791/59370.
676 Exploring novel therapeutic targets in the treatment of cutaneous T-cell lymphomaYumeen S, King A, Kim S, Lewis J, Carlson K, Umlauf S, Surovtseva Y, Foss F, Girardi M. 676 Exploring novel therapeutic targets in the treatment of cutaneous T-cell lymphoma. Journal Of Investigative Dermatology 2019, 139: s116. DOI: 10.1016/j.jid.2019.03.752.
System-level variations in treatment delay for nonmetastatic melanomaCheraghlou S, Agogo GO, Girardi M. System-level variations in treatment delay for nonmetastatic melanoma. Journal Of The American Academy Of Dermatology 2019, 81: 1399-1401. PMID: 31009671, DOI: 10.1016/j.jaad.2019.04.038.
108 Efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies: results from the PROVe studyKim E, Geskin L, Querfeld C, Girardi M, Mink D, Williams M, Angello J, Bailey W. 108 Efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies: results from the PROVe study. European Journal Of Cancer 2019, 119: s39. DOI: 10.1016/s0959-8049(19)30618-5.
Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survivalCheraghlou S, Agogo GO, Girardi M. Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival. Journal Of The American Academy Of Dermatology 2018, 80: 979-989. PMID: 30365997, DOI: 10.1016/j.jaad.2018.10.026.
Disease site as a prognostic factor for mycosis fungoides: an analysis of 2428 cases from the US National Cancer DatabaseSu C, Tang R, Bai HX, Girardi M, Karakousis G, Zhang PJ, Xiao R, Zhang G. Disease site as a prognostic factor for mycosis fungoides: an analysis of 2428 cases from the US National Cancer Database. British Journal Of Haematology 2018, 185: 592-595. PMID: 30216417, DOI: 10.1111/bjh.15570.
LB1550 Skin commensals as instigators of cutaneous T cell lymphomaDehner C, Ruff W, Foss F, Girardi M, Kriegel M. LB1550 Skin commensals as instigators of cutaneous T cell lymphoma. Journal Of Investigative Dermatology 2018, 138: b14. DOI: 10.1016/j.jid.2018.06.086.
Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anti-Cancer ImmunityVentura A, Vassall A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anti-Cancer Immunity. Cancer Research 2018, 78: canres.0171.2018. PMID: 29764863, DOI: 10.1158/0008-5472.can-18-0171.
Biodegradable bioadhesive nanoparticle incorporation of broad‐spectrum organic sunscreen agentsSuh H, Lewis J, Fong L, Ramseier JY, Carlson K, Peng Z, Yin ES, Saltzman WM, Girardi M. Biodegradable bioadhesive nanoparticle incorporation of broad‐spectrum organic sunscreen agents. Bioengineering & Translational Medicine 2018, 4: 129-140. PMID: 30680324, PMCID: PMC6336670, DOI: 10.1002/btm2.10092.
An Integrated Data Resource for Genomic Analysis of Cutaneous T-Cell LymphomaChang LW, Patrone CC, Yang W, Rabionet R, Gallardo F, Espinet B, Sharma MK, Girardi M, Tensen CP, Vermeer M, Geskin LJ. An Integrated Data Resource for Genomic Analysis of Cutaneous T-Cell Lymphoma. Journal Of Investigative Dermatology 2018, 138: 2681-2683. PMID: 29981755, DOI: 10.1016/j.jid.2018.06.176.
Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of PralatrexateFoss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma Myeloma & Leukemia 2018, 18: e445-e447. PMID: 30181105, DOI: 10.1016/j.clml.2018.06.020.
BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibitionKim R, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Oncotarget 2018, 9: 29193-29207. PMID: 30018745, PMCID: PMC6044378, DOI: 10.18632/oncotarget.25670.
452 BET inhibition markedly inhibits CTCL cell viability and is synergistically potentiated by BCL2 or HDAC inhibitionKim S, Cyrenne B, Lewis J, Monico P, Mirza F, Carlson K, Foss F, Girardi M. 452 BET inhibition markedly inhibits CTCL cell viability and is synergistically potentiated by BCL2 or HDAC inhibition. Journal Of Investigative Dermatology 2018, 138: s77. DOI: 10.1016/j.jid.2018.03.459.
1070 Biodegradable bioadhesive nanoparticle delivery of camptothecin for the treatment of PDV squamous cell carcinomaLee A, Suh H, Yin E, Lewis J, Saltzman W, Girardi M. 1070 Biodegradable bioadhesive nanoparticle delivery of camptothecin for the treatment of PDV squamous cell carcinoma. Journal Of Investigative Dermatology 2018, 138: s181. DOI: 10.1016/j.jid.2018.03.1083.
Pillars Article: Regulation of Cutaneous Malignancy by γδ T Cells. Science. 2001. 294: 605-609.Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Pillars Article: Regulation of Cutaneous Malignancy by γδ T Cells. Science. 2001. 294: 605-609. The Journal Of Immunology 2018, 200: 3031-3035. PMID: 29685949.
Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinibKim R, Charos A, Damsky W, Heald P, Girardi M, King BA. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Reports 2018, 4: 443-445. PMID: 29984277, PMCID: PMC6031588, DOI: 10.1016/j.jdcr.2017.12.003.
Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupusGreiling TM, Dehner C, Chen X, Hughes K, Iñiguez AJ, Boccitto M, Ruiz DZ, Renfroe SC, Vieira SM, Ruff WE, Sim S, Kriegel C, Glanternik J, Chen X, Girardi M, Degnan P, Costenbader KH, Goodman AL, Wolin SL, Kriegel MA. Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus. Science Translational Medicine 2018, 10 PMID: 29593104, PMCID: PMC5918293, DOI: 10.1126/scitranslmed.aan2306.
441 Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic MalignanciesIsufi I, Seropian S, Cooper D, Roberts K, Wilson L, Girardi M, Perreault S, Foss F. 441 Reduced Intensity Conditioning with Pentostatin and Low-Dose TBI in Patients with Relapsed Hematologic Malignancies. Transplantation And Cellular Therapy 2018, 24: s307. DOI: 10.1016/j.bbmt.2017.12.353.
Predicting non-melanoma skin cancer via a multi-parameterized artificial neural networkRoffman D, Hart G, Girardi M, Ko CJ, Deng J. Predicting non-melanoma skin cancer via a multi-parameterized artificial neural network. Scientific Reports 2018, 8: 1701. PMID: 29374196, PMCID: PMC5786038, DOI: 10.1038/s41598-018-19907-9.
Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell LymphomaCyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.
Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotinCyrenne BM, Subtil A, Girardi M, Foss F. Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin. International Journal Of Dermatology 2017, 56: 1448-1450. PMID: 29047111, DOI: 10.1111/ijd.13792.
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patientsCyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 2017, 130: 2073-2083. PMID: 28972015, PMCID: PMC5680613, DOI: 10.1182/blood-2017-06-792150.
Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary SyndromeKann B, Park H, Yeboa D, Aneja S, Girardi M, Foss F, Roberts K, Wilson L. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e430. DOI: 10.1016/j.ijrobp.2017.06.1632.
Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary SyndromeKann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 520-526.e2. PMID: 28655598, DOI: 10.1016/j.clml.2017.05.017.
694 Combination Bcl-2 and HDAC inhibition in the treatment of cutaneous T-cell lymphomaCyrenne B, Lewis J, Weed J, Mirza F, Carlson K, Girardi M. 694 Combination Bcl-2 and HDAC inhibition in the treatment of cutaneous T-cell lymphoma. Journal Of Investigative Dermatology 2017, 137: s119. DOI: 10.1016/j.jid.2017.02.717.
666 Biodegradable poly(lactic acid)-hyperbranched polyglycerol nanoparticle encapsulated drug delivery for skin cancer treatmentYin E, Lewis J, Suh H, Saltzman W, Girardi M. 666 Biodegradable poly(lactic acid)-hyperbranched polyglycerol nanoparticle encapsulated drug delivery for skin cancer treatment. Journal Of Investigative Dermatology 2017, 137: s115. DOI: 10.1016/j.jid.2017.02.689.
146 UV-induced mutant p53 keratinocyte clonal expansion dependence on IL22 and RORγtLewis J, Monico P, Turban J, Girardi M. 146 UV-induced mutant p53 keratinocyte clonal expansion dependence on IL22 and RORγt. Journal Of Investigative Dermatology 2017, 137: s25. DOI: 10.1016/j.jid.2017.02.160.
761 Development of a novel broad-spectrum sunscreen via bioadhesive nanoparticle encapsulation of organic UV filtersSuh H, Lewis J, Fong L, Carlson K, Ramseier J, Saltzman W, Girardi M. 761 Development of a novel broad-spectrum sunscreen via bioadhesive nanoparticle encapsulation of organic UV filters. Journal Of Investigative Dermatology 2017, 137: s131. DOI: 10.1016/j.jid.2017.02.785.
Mycosis Fungoides and Sezary SyndromeFoss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome. Hematology/Oncology Clinics Of North America 2017, 31: 297-315. PMID: 28340880, DOI: 10.1016/j.hoc.2016.11.008.
Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomasGuitart J, Martinez-Escala ME, Subtil A, Duvic M, Pulitzer MP, Olsen EA, Kim E, Rook AH, Samimi SS, Wood GS, Girardi M, Junkins-Hopkins J, Ivan DS, Selim MA, Sable KA, Virmani P, Pincus LB, Tetzlaff MT, Kim J, Kim YH. Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. Modern Pathology 2017, 30: 761-772. PMID: 28128277, PMCID: PMC5413429, DOI: 10.1038/modpathol.2016.240.
FISH Panel for Leukemic CTCLWeed J, Gibson J, Lewis J, Carlson K, Foss F, Choi J, Li P, Girardi M. FISH Panel for Leukemic CTCL. Journal Of Investigative Dermatology 2016, 137: 751-753. PMID: 27836797, PMCID: PMC5419071, DOI: 10.1016/j.jid.2016.10.037.
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 ImmunotherapyShi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatology 2016, 152: 1128-1136. PMID: 27411054, PMCID: PMC6108080, DOI: 10.1001/jamadermatol.2016.2226.
Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cellsKibbi N, Sobolev O, Girardi M, Edelson RL. Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells. Transfusion And Apheresis Science 2016, 55: 146-152. PMID: 27317354, DOI: 10.1016/j.transci.2016.06.001.
307 UVB-induced HMGB1 and extracellular ATP increase Langerhans cell production of IL-23 implicated in ILC3 activationTurban J, Lewis J, Girardi M. 307 UVB-induced HMGB1 and extracellular ATP increase Langerhans cell production of IL-23 implicated in ILC3 activation. Journal Of Investigative Dermatology 2016, 136: s54. DOI: 10.1016/j.jid.2016.02.338.
071 Novel FISH probe panel for the detection of gene copy number alterations in CTCLWeed J, Gibson J, Lewis J, Carlson K, Foss F, Choi J, Li P, Girardi M. 071 Novel FISH probe panel for the detection of gene copy number alterations in CTCL. Journal Of Investigative Dermatology 2016, 136: s13. DOI: 10.1016/j.jid.2016.02.097.
234 Anti-Ro60 T and B cells in human lupus cross-react with Ro60 orthologs from cutaneous commensalsGreiling T, Dehner C, Renfroe S, Chen X, Vieira S, Ruff W, Girardi M, Goodman A, Wolin S, Kriegel M. 234 Anti-Ro60 T and B cells in human lupus cross-react with Ro60 orthologs from cutaneous commensals. Journal Of Investigative Dermatology 2016, 136: s42. DOI: 10.1016/j.jid.2016.02.263.
591 Langerhans cells and UV radiation drive local IL-22+ ILC3 in association with enhanced cutaneous carcinogenesisLewis J, Turban J, Girardi M. 591 Langerhans cells and UV radiation drive local IL-22+ ILC3 in association with enhanced cutaneous carcinogenesis. Journal Of Investigative Dermatology 2016, 136: s105. DOI: 10.1016/j.jid.2016.02.630.
Diverse cutaneous manifestations of Erdheim-Chester disease in a woman with a history of Langerhans cell histiocytosisNeckman JP, Kim J, Mathur M, Myung P, Girardi M. Diverse cutaneous manifestations of Erdheim-Chester disease in a woman with a history of Langerhans cell histiocytosis. JAAD Case Reports 2016, 2: 128-131. PMID: 27051852, PMCID: PMC4810280, DOI: 10.1016/j.jdcr.2015.10.010.
Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restrictionGibson JF, Huang J, Liu KJ, Carlson KR, Foss F, Choi J, Edelson R, Hussong JW, Mohl R, Hill S, Girardi M. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. Journal Of The American Academy Of Dermatology 2016, 74: 870-877. PMID: 26874819, PMCID: PMC4835257, DOI: 10.1016/j.jaad.2015.12.018.
The difficult—and often delayed—diagnosis of CTCLWeed J, Girardi M. The difficult—and often delayed—diagnosis of CTCL. Science Translational Medicine 2015, 7: 308fs41. PMID: 26446952, DOI: 10.1126/scitranslmed.aad2518.
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic ModelScarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal Of Clinical Oncology 2015, 33: 3766-3773. PMID: 26438120, PMCID: PMC4979132, DOI: 10.1200/jco.2015.61.7142.
A sunblock based on bioadhesive nanoparticlesDeng Y, Ediriwickrema A, Yang F, Lewis J, Girardi M, Saltzman WM. A sunblock based on bioadhesive nanoparticles. Nature Materials 2015, 14: 1278-1285. PMID: 26413985, PMCID: PMC4654636, DOI: 10.1038/nmat4422.
Genomic landscape of cutaneous T cell lymphomaChoi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic landscape of cutaneous T cell lymphoma. Nature Genetics 2015, 47: 1011-1019. PMID: 26192916, PMCID: PMC4552614, DOI: 10.1038/ng.3356.
Langerhans Cells Facilitate UVB-Induced Epidermal CarcinogenesisLewis JM, Bürgler CD, Freudzon M, Golubets K, Gibson JF, Filler RB, Girardi M. Langerhans Cells Facilitate UVB-Induced Epidermal Carcinogenesis. Journal Of Investigative Dermatology 2015, 135: 2824-2833. PMID: 26053049, PMCID: PMC4640962, DOI: 10.1038/jid.2015.207.
Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphomaGibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, Foss F. Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. Journal Of The American Academy Of Dermatology 2015, 72: 1010-1015.e5. PMID: 25981001, DOI: 10.1016/j.jaad.2015.01.003.
Posttraumatic EczemaGreiling TM, Galan A, Girardi M, Watsky KL. Posttraumatic Eczema. Dermatitis 2014, 25: 376-377. PMID: 25384225, PMCID: PMC4865885, DOI: 10.1097/der.0000000000000088.
Mechanisms of Chemical Cooperative Carcinogenesis by Epidermal Langerhans CellsLewis JM, Bürgler CD, Fraser JA, Liao H, Golubets K, Kucher CL, Zhao PY, Filler RB, Tigelaar RE, Girardi M. Mechanisms of Chemical Cooperative Carcinogenesis by Epidermal Langerhans Cells. Journal Of Investigative Dermatology 2014, 135: 1405-1414. PMID: 25233073, PMCID: PMC4364923, DOI: 10.1038/jid.2014.411.
CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literatureJames E, Sokhn JG, Gibson JF, Carlson K, Subtil A, Girardi M, Wilson LD, Foss F. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leukemia & Lymphoma 2014, 56: 951-957. PMID: 24996443, DOI: 10.3109/10428194.2014.938331.
ECP activation of monocytes by fibronectinGonzalez AL, Berger CL, Remington J, Girardi M, Tigelaar RE, Edelson RL. ECP activation of monocytes by fibronectin. Clinical & Experimental Immunology 2014, 175: 449-457. PMID: 24188174, PMCID: PMC3927905, DOI: 10.1111/cei.12231.
IL-9 Regulates Allergen-Specific Th1 Responses in Allergic Contact DermatitisLiu J, Harberts E, Tammaro A, Girardi N, Filler RB, Fishelevich R, Temann A, Licona-Limón P, Girardi M, Flavell RA, Gaspari AA. IL-9 Regulates Allergen-Specific Th1 Responses in Allergic Contact Dermatitis. Journal Of Investigative Dermatology 2014, 134: 1903-1911. PMID: 24487305, PMCID: PMC4303591, DOI: 10.1038/jid.2014.61.
Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: Initiation via direct platelet signalingDurazzo TS, Tigelaar RE, Filler R, Hayday A, Girardi M, Edelson RL. Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: Initiation via direct platelet signaling. Transfusion And Apheresis Science 2013, 50: 370-378. PMID: 24360371, PMCID: PMC4167725, DOI: 10.1016/j.transci.2013.11.008.
Acute Treatment Toxicity and the Risk of Infection During Total Skin Electron Beam Therapy for Mycosis FungoidesLloyd S, Chen Z, Foss F, Girardi M, Wilson L. Acute Treatment Toxicity and the Risk of Infection During Total Skin Electron Beam Therapy for Mycosis Fungoides. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s557. DOI: 10.1016/j.ijrobp.2013.06.1475.
Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoidesLloyd S, Chen Z, Foss FM, Girardi M, Wilson LD. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. Journal Of The American Academy Of Dermatology 2013, 69: 537-543. PMID: 23849563, DOI: 10.1016/j.jaad.2013.04.063.
Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.Huang J, Cowper S, Moss J, Girardi M. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides. Journal Of Drugs In Dermatology 2013, 12: 487-9. PMID: 23652902.
Periorificial Dermatitis and Erosive Inguinal Plaques in a 57-Year-Old Woman—Quiz CaseLott JP, Reeve J, Ko C, Girardi M. Periorificial Dermatitis and Erosive Inguinal Plaques in a 57-Year-Old Woman—Quiz Case. JAMA Dermatology 2013, 149: 358-363. PMID: 23552816, DOI: 10.1001/archderm.149.3.358-b.
Development of a Plaque Infiltrated With Large CD30+ T Cells Over a Silicone-Containing Device in a Patient With History of Sézary SyndromeEngberg AK, Bunick CG, Subtil A, Ko CJ, Girardi M. Development of a Plaque Infiltrated With Large CD30+ T Cells Over a Silicone-Containing Device in a Patient With History of Sézary Syndrome. Journal Of Clinical Oncology 2012, 31: e87-e89. PMID: 23182990, PMCID: PMC4855504, DOI: 10.1200/jco.2012.42.9241.
Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell LymphomaParker T, Barbarotta L, Girardi M, Foss F. Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma. Blood 2012, 120: 3660. DOI: 10.1182/blood.v120.21.3660.3660.
Immunotherapy for Cutaneous T-Cell LymphomaModi B, Foss F, Edelson R, Girardi M. Immunotherapy for Cutaneous T-Cell Lymphoma. 2012, 307-316. DOI: 10.1007/978-1-62703-170-7_18.
Langerhans Cells Facilitate Epithelial DNA Damage and Squamous Cell CarcinomaModi BG, Neustadter J, Binda E, Lewis J, Filler RB, Roberts SJ, Kwong BY, Reddy S, Overton JD, Galan A, Tigelaar R, Cai L, Fu P, Shlomchik M, Kaplan DH, Hayday A, Girardi M. Langerhans Cells Facilitate Epithelial DNA Damage and Squamous Cell Carcinoma. Science 2012, 335: 104-108. PMID: 22223807, PMCID: PMC3753811, DOI: 10.1126/science.1211600.
Dialogues in Dermatology: Highlights from 2011Lott JP, Robinson D, Warren C, Klein R, Craiglow B, Girardi M. Dialogues in Dermatology: Highlights from 2011. Journal Of The American Academy Of Dermatology 2012, 66: 153-156. PMID: 22177634, DOI: 10.1016/j.jaad.2011.10.018.
“Extracorporeal Photochemotherapy” in Comprehensive Dermatologic Drug TherapyGirardi M, Choi J, Heald PW. “Extracorporeal Photochemotherapy” in Comprehensive Dermatologic Drug Therapy, S. Wolvertin, (ed), 3rd Ed. W.B. Saunders, Philadelphia, 2012.
Mycosis fungoides exhibiting features of a dermatofibroma: a case report and review of the literatureMorcos SM, Girardi M, Subtil A, Wilson LD, Cowper SE. Mycosis fungoides exhibiting features of a dermatofibroma: a case report and review of the literature. Journal Of Cutaneous Pathology 2011, 39: 40-46. PMID: 22059953, DOI: 10.1111/j.1600-0560.2011.01804.x.
MicroRNA Profiling of Cutaneous T-cell Lymphoma Cell Lines: Implications for Pathophysiology and TherapyHansen J, Reza F, Nallur S, Lewis J, Carlson K, Lin W, Weidhaas J, Wilson L, Girardi M. MicroRNA Profiling of Cutaneous T-cell Lymphoma Cell Lines: Implications for Pathophysiology and Therapy. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s22. DOI: 10.1016/j.ijrobp.2011.06.045.
Characterization of the DNA Copy-Number Genome in the Blood of Cutaneous T-Cell Lymphoma PatientsLin WM, Lewis JM, Filler RB, Modi BG, Carlson KR, Reddy S, Thornberg A, Saksena G, Umlauf S, Oberholzer PA, Karpova M, Getz G, Mane S, Garraway LA, Dummer R, Berger CL, Edelson RL, Girardi M. Characterization of the DNA Copy-Number Genome in the Blood of Cutaneous T-Cell Lymphoma Patients. Journal Of Investigative Dermatology 2011, 132: 188-197. PMID: 21881587, PMCID: PMC3841973, DOI: 10.1038/jid.2011.254.
Practice Gaps —The Hard Task of Measuring Cutaneous FibrosisLott JP, Girardi M. Practice Gaps —The Hard Task of Measuring Cutaneous Fibrosis. JAMA Dermatology 2011, 147: 1115-1116. PMID: 21931058, DOI: 10.1001/archdermatol.2011.244.
Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendationsGirardi M, Kay J, Elston DM, LeBoit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. Journal Of The American Academy Of Dermatology 2011, 65: 1095-1106.e7. PMID: 21724294, DOI: 10.1016/j.jaad.2010.08.041.
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerOlsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal Of Clinical Oncology 2011, 29: 2598-2607. PMID: 21576639, PMCID: PMC3422534, DOI: 10.1200/jco.2010.32.0630.
Response: validity of evidence demonstrating efficacy of extracorporeal photochemotherapyBerger C, Lewis J, Girardi M, Tigelaar R, Edelson R. Response: validity of evidence demonstrating efficacy of extracorporeal photochemotherapy. Blood 2011, 117: 367. PMID: 21212292, PMCID: PMC3037285, DOI: 10.1182/blood-2010-11-317107.
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascadeKießling M, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, Girardi M, MacConaill LE, Kehoe SM, Hatton C, French LE, Garraway LA, Polier G, Süss D, Klemke CD, Krammer PH, Gülow K, Dummer R. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood 2011, 117: 2433-2440. PMID: 21209378, PMCID: PMC3952811, DOI: 10.1182/blood-2010-09-305128.
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphomaKim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 2010, 63: 975-983. PMID: 20888065, DOI: 10.1016/j.jaad.2009.12.052.
Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literatureCuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrology Dialysis Transplantation 2010, 26: 1099-1101. PMID: 21079195, DOI: 10.1093/ndt/gfq693.
The contribution of Langerhans cells to cutaneous malignancyLewis J, Filler R, Smith DA, Golubets K, Girardi M. The contribution of Langerhans cells to cutaneous malignancy. Trends In Immunology 2010, 31: 460-466. PMID: 21071271, PMCID: PMC3753793, DOI: 10.1016/j.it.2010.10.001.
Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapyBerger C, Hoffmann K, Vasquez JG, Mane S, Lewis J, Filler R, Lin A, Zhao H, Durazzo T, Baird A, Lin W, Foss F, Christensen I, Girardi M, Tigelaar R, Edelson R. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood 2010, 116: 4838-4847. PMID: 20720185, PMCID: PMC3321745, DOI: 10.1182/blood-2009-11-256040.
The Clinical Spectrum of Nephrogenic Systemic FibrosisM. Elston D, Girardi M. The Clinical Spectrum of Nephrogenic Systemic Fibrosis. Current Rheumatology Reviews 2010, 6: 176-179. DOI: 10.2174/157339710791792702.
A transient epidermolysis bullosa simplex‐like phenotype associated with bexarotene treatment in a G138E KRT5 heterozygoteTrufant JW, Kreizenbeck GM, Carlson KR, Muthusamy V, Girardi M, Bosenberg MW. A transient epidermolysis bullosa simplex‐like phenotype associated with bexarotene treatment in a G138E KRT5 heterozygote. Journal Of Cutaneous Pathology 2010, 37: 1155-1160. PMID: 20849457, DOI: 10.1111/j.1600-0560.2010.01557.x.
More or Less: Copy Number Alterations in Mycosis FungoidesLin WM, Girardi M. More or Less: Copy Number Alterations in Mycosis Fungoides. Journal Of Investigative Dermatology 2010, 130: 926-928. PMID: 20231832, DOI: 10.1038/jid.2009.370.
Molecular Analysis of Tumor-Promoting CD8+ T Cells in Two-Stage Cutaneous Chemical CarcinogenesisKwong BY, Roberts SJ, Silberzahn T, Filler RB, Neustadter JH, Galan A, Reddy S, Lin WM, Ellis PD, Langford CF, Hayday AC, Girardi M. Molecular Analysis of Tumor-Promoting CD8+ T Cells in Two-Stage Cutaneous Chemical Carcinogenesis. Journal Of Investigative Dermatology 2009, 130: 1726-1736. PMID: 19924136, PMCID: PMC2920801, DOI: 10.1038/jid.2009.362.
Addition of TSEBT to ECP Reduces Circulating Malignant Cells in Leukemic Cutaneous T-cell LymphomaHansen J, Wilson L, Carlson K, Girardi M. Addition of TSEBT to ECP Reduces Circulating Malignant Cells in Leukemic Cutaneous T-cell Lymphoma. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s480-s481. DOI: 10.1016/j.ijrobp.2009.07.1097.
Primary Cutaneous Aspergillosis in an Immunocompetent Patient: Successful Treatment with Oral VoriconazoleCRAIGLOW B, HINDS G, ANTAYA R, GIRARDI M. Primary Cutaneous Aspergillosis in an Immunocompetent Patient: Successful Treatment with Oral Voriconazole. Pediatric Dermatology 2009, 26: 493-495. PMID: 19689543, DOI: 10.1111/j.1525-1470.2009.00971.x.
MRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reductionKuo P, Abu-Alfa A, Bucala R, Griffith J, Carlson K, Girardi M, Weinreb J, Cowper S. MRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reduction. Applied Radiology 2009, 22-33. DOI: 10.37549/ar1683.
CD27 is a thymic determinant of the balance between interferon-γ- and interleukin 17–producing γδ T cell subsetsRibot JC, deBarros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ, Girardi M, Borst J, Hayday AC, Pennington DJ, Silva-Santos B. CD27 is a thymic determinant of the balance between interferon-γ- and interleukin 17–producing γδ T cell subsets. Nature Immunology 2009, 10: 427-436. PMID: 19270712, PMCID: PMC4167721, DOI: 10.1038/ni.1717.
Extracorporeal Photochemotherapy for Generalized Deep MorpheaNeustadter JH, Samarin F, Carlson KR, Girardi M. Extracorporeal Photochemotherapy for Generalized Deep Morphea. JAMA Dermatology 2009, 145: 127-130. PMID: 19221256, PMCID: PMC4075155, DOI: 10.1001/archdermatol.2008.547.
Abstracts of the Otorhinolaryngological Research Society Meeting Autumn Meeting26th September 2008, UCL Ear Institute, Gray's Inn Road, LondonPrasad S, Cody V, Hanlon D, Roberts S, Filler R, Edelson R, Dobrucki W, Sinusas A, Girardi M, Birchall M. Abstracts of the Otorhinolaryngological Research Society Meeting Autumn Meeting26th September 2008, UCL Ear Institute, Gray's Inn Road, London. Clinical Otolaryngology 2008, 33: 644-644. DOI: 10.1111/j.1749-4486.2008.01843_11.x.
Pemphigoid vegetans: a case report and review of the literatureKim J, Chavel S, Girardi M, McNiff JM. Pemphigoid vegetans: a case report and review of the literature. Journal Of Cutaneous Pathology 2008, 35: 1144-1147. PMID: 18988318, DOI: 10.1111/j.1600-0560.2008.01016.x.
FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II TrialKuo PH, Carlson KR, Christensen I, Girardi M, Heald PW. FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. Molecular Imaging And Biology 2008, 10: 306-314. PMID: 18665425, DOI: 10.1007/s11307-008-0161-4.
Scleroderma-Like Illness as a Presenting Feature of Multiple Myeloma and AmyloidosisReyes CM, Rudinskaya A, Kloss R, Girardi M, Lazova R. Scleroderma-Like Illness as a Presenting Feature of Multiple Myeloma and Amyloidosis. JCR Journal Of Clinical Rheumatology 2008, 14: 161-165. PMID: 18525436, DOI: 10.1097/rhu.0b013e3181775a15.
Skint1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epidermal γδ T cellsBoyden LM, Lewis JM, Barbee SD, Bas A, Girardi M, Hayday AC, Tigelaar RE, Lifton RP. Skint1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epidermal γδ T cells. Nature Genetics 2008, 40: 656-662. PMID: 18408721, PMCID: PMC4167720, DOI: 10.1038/ng.108.
Clinical and histological findings in nephrogenic systemic fibrosisCowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. European Journal Of Radiology 2008, 66: 191-199. PMID: 18325705, DOI: 10.1016/j.ejrad.2008.01.016.
Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities.Berger CL, Heald P, Girardi M, Edelson RL. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. Giornale Italiano Di Dermatologia E Venereologia 2008, 143: 43-54. PMID: 18833050.
FDG-PET/CT in the Evaluation of Cutaneous T-Cell LymphomaKuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW, Girardi M. FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma. Molecular Imaging And Biology 2008, 10: 74-81. PMID: 18196347, DOI: 10.1007/s11307-007-0127-y.
Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesisStrid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, Kaplan DH, Hayday AC, Girardi M. Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nature Immunology 2008, 9: 146-154. PMID: 18176566, DOI: 10.1038/ni1556.
Conventional and Unconventional T CellsRoberts S, Girardi M. Conventional and Unconventional T Cells. 2008, 85-104. DOI: 10.1007/978-1-84800-165-7_6.
Nephrogenic Systemic Fibrosis: A Dermatologist’s PerspectiveGirardi M. Nephrogenic Systemic Fibrosis: A Dermatologist’s Perspective. Journal Of The American College Of Radiology 2008, 5: 40-44. PMID: 18180008, DOI: 10.1016/j.jacr.2007.08.017.
Cutaneous Perspectives on Adaptive ImmunityGirardi M. Cutaneous Perspectives on Adaptive Immunity. Clinical Reviews In Allergy & Immunology 2007, 33: 4-14. PMID: 18094943, DOI: 10.1007/s12016-007-0040-9.
Cutaneous two-stage chemical carcinogenesis.Filler RB, Roberts SJ, Girardi M. Cutaneous two-stage chemical carcinogenesis. Cold Spring Harbor Protocols 2007, 2007: pdb.prot4837. PMID: 21357170, DOI: 10.1101/pdb.prot4837.
Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesisRoberts SJ, Ng BY, Filler RB, Lewis J, Glusac EJ, Hayday AC, Tigelaar RE, Girardi M. Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2007, 104: 6770-6775. PMID: 17412837, PMCID: PMC1871860, DOI: 10.1073/pnas.0604982104.
Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB miceWakabayashi Y, Mao JH, Brown K, Girardi M, Balmain A. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature 2007, 445: 761-765. PMID: 17230190, DOI: 10.1038/nature05489.
A systematic review of the safety of topical therapies for atopic dermatitisCallen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M, Hanifin J, Lee P, Margolis D, Paller AS, Piacquadio D, Peterson W, Kaulback K, Fennerty M, Wintroub BU. A systematic review of the safety of topical therapies for atopic dermatitis. British Journal Of Dermatology 2006, 156: 203-221. PMID: 17223859, DOI: 10.1111/j.1365-2133.2006.07538.x.
Selection of the cutaneous intraepithelial γδ+ T cell repertoire by a thymic stromal determinantLewis JM, Girardi M, Roberts SJ, D Barbee S, Hayday AC, Tigelaar RE. Selection of the cutaneous intraepithelial γδ+ T cell repertoire by a thymic stromal determinant. Nature Immunology 2006, 7: 843-850. PMID: 16829962, DOI: 10.1038/ni1363.
The therapeutic potential of extracorporeal photopheresis.Girardi M. The therapeutic potential of extracorporeal photopheresis. Clinical Advances In Hematology & Oncology : H&O 2006, 4: 349-50. PMID: 16728944.
Environmentally Responsive and Reversible Regulation of Epidermal Barrier Function by γδ T CellsGirardi M, Lewis JM, Filler RB, Hayday AC, Tigelaar RE. Environmentally Responsive and Reversible Regulation of Epidermal Barrier Function by γδ T Cells. Journal Of Investigative Dermatology 2006, 126: 808-814. PMID: 16439970, DOI: 10.1038/sj.jid.5700120.
Transimmunization for cutaneous T cell lymphoma: A phase I studyGirardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: A phase I study. Leukemia & Lymphoma 2006, 47: 1495-1503. PMID: 16966259, DOI: 10.1080/10428190600581419.
Immunosurveillance and Immunoregulation by γδ T CellsGirardi M. Immunosurveillance and Immunoregulation by γδ T Cells. Journal Of Investigative Dermatology 2006, 126: 25-31. PMID: 16417214, DOI: 10.1038/sj.jid.5700003.
Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillanceOppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nature Immunology 2005, 6: 928-937. PMID: 16116470, DOI: 10.1038/ni1239.
Cross-Comparison of Patch Test and Lymphocyte Proliferation Responses in Patients With a History of Acute Generalized Exanthematous PustulosisGirardi M, Duncan KO, Tigelaar RE, Imaeda S, Watsky KL, McNiff JM. Cross-Comparison of Patch Test and Lymphocyte Proliferation Responses in Patients With a History of Acute Generalized Exanthematous Pustulosis. American Journal Of Dermatopathology 2005, 27: 343-346. PMID: 16121058, DOI: 10.1097/01.dad.0000160982.75176.6c.
Immunosurveillance by γδ T Cells: Focus on the Murine SystemGirardi M, Hayday AC. Immunosurveillance by γδ T Cells: Focus on the Murine System. 2005, 86: 136-150. PMID: 15976492, DOI: 10.1159/000086658.
TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909.Kim Y, Girardi M, Duvic M, Kuzel T, Rook A, Link B, Pinter-Brown L, Comerci C, McAuley S, Schmalbach T. TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909. Blood 2004, 104: 743. DOI: 10.1182/blood.v104.11.743.743.
Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CPG immunomodulator (CPG 7909), a phase I studyKim Y, Girardi M, McAuley S, Schmalbach T. Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CPG immunomodulator (CPG 7909), a phase I study. Journal Of Clinical Oncology 2004, 22: 6600-6600. DOI: 10.1200/jco.2004.22.90140.6600.
Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CPG immunomodulator (CPG 7909), a phase I studyKim Y, Girardi M, McAuley S, Schmalbach T. Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CPG immunomodulator (CPG 7909), a phase I study. Journal Of Clinical Oncology 2004, 22: 6600-6600. DOI: 10.1200/jco.2004.22.14_suppl.6600.
The Pathogenesis of Mycosis FungoidesGirardi M, Heald PW, Wilson LD. The Pathogenesis of Mycosis Fungoides. New England Journal Of Medicine 2004, 350: 1978-1988. PMID: 15128898, DOI: 10.1056/nejmra032810.
Characterizing the Protective Component of the αβ T Cell Response to Transplantable Squamous Cell CarcinomaGirardi M, Oppenheim D, Glusac EJ, Filler R, Balmain A, Tigelaar RE, Hayday AC. Characterizing the Protective Component of the αβ T Cell Response to Transplantable Squamous Cell Carcinoma. Journal Of Investigative Dermatology 2004, 122: 699-706. PMID: 15086556, DOI: 10.1111/j.0022-202x.2004.22342.x.
Cutaneous biology of gammadelta T cells.Girardi M. Cutaneous biology of gammadelta T cells. Advances In Dermatology 2004, 20: 203-15. PMID: 15544201.
Advances in understanding the immunobiology and immunotherapy of cutaneous T-cell lymphoma.Berger CL, Mariwalla K, Girardi M, Edelson RL. Advances in understanding the immunobiology and immunotherapy of cutaneous T-cell lymphoma. Advances In Dermatology 2004, 20: 217-35. PMID: 15544202.
Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrowGirardi M, Knobler R, Edelson R. Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. Hematology/Oncology Clinics Of North America 2003, 17: 1391-1403. PMID: 14710891, DOI: 10.1016/s0889-8588(03)00106-0.
The Distinct Contributions of Murine T Cell Receptor (TCR)γδ+ and TCRαβ+ T Cells to Different Stages of Chemically Induced Skin CancerGirardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, Tigelaar RE, Hayday AC. The Distinct Contributions of Murine T Cell Receptor (TCR)γδ+ and TCRαβ+ T Cells to Different Stages of Chemically Induced Skin Cancer. Journal Of Experimental Medicine 2003, 198: 747-755. PMID: 12953094, PMCID: PMC2194182, DOI: 10.1084/jem.20021282.
γδ T Cells Provide an Early Source of Interferon γ in Tumor ImmunityGao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, Craft J, Yin Z. γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity. Journal Of Experimental Medicine 2003, 198: 433-442. PMID: 12900519, PMCID: PMC2194096, DOI: 10.1084/jem.20030584.
Anti‐inflammatory effects in the skin of thymosin‐β4 splice‐variantsGirardi M, Sherling MA, Filler RB, Shires J, Theodoridis E, Hayday AC, Tigelaar RE. Anti‐inflammatory effects in the skin of thymosin‐β4 splice‐variants. Immunology 2003, 109: 1-7. PMID: 12709011, PMCID: PMC1782938, DOI: 10.1046/j.1365-2567.2003.01616.x.
Transimmunization, a novel approach for tumor immunotherapyBerger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. Transfusion And Apheresis Science 2002, 26: 205-216. PMID: 12126207, DOI: 10.1016/s1473-0502(02)00014-9.
Transimmunization and the evolution of extracorporeal photochemotherapyGirardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Transfusion And Apheresis Science 2002, 26: 181-190. PMID: 12126204, DOI: 10.1016/s1473-0502(02)00011-3.
Resident Skin-specific γδ T Cells Provide Local, Nonredundant Regulation of Cutaneous InflammationGirardi M, Lewis J, Glusac E, Filler RB, Geng L, Hayday AC, Tigelaar RE. Resident Skin-specific γδ T Cells Provide Local, Nonredundant Regulation of Cutaneous Inflammation. Journal Of Experimental Medicine 2002, 195: 855-867. PMID: 11927630, PMCID: PMC2193718, DOI: 10.1084/jem.20012000.
Efficient Tumor Antigen Loading of Dendritic Antigen Presenting Cells by TransimmunizationGirardi M, Berger C, Hanlon D, Edelson RL. Efficient Tumor Antigen Loading of Dendritic Antigen Presenting Cells by Transimmunization. Technology In Cancer Research & Treatment 2002, 1: 65-69. PMID: 12614179, DOI: 10.1177/153303460200100109.
Regulation of Cutaneous Malignancy by γδ T CellsGirardi M, Oppenheim D, Steele C, Lewis J, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar R, Hayday A. Regulation of Cutaneous Malignancy by γδ T Cells. Science 2001, 294: 605-609. PMID: 11567106, DOI: 10.1126/science.1063916.
Extracorporeal Photochemoimmunotherapy in Cutaneous T Cell LymphomasKNOBLER R, GIRARDI M. Extracorporeal Photochemoimmunotherapy in Cutaneous T Cell Lymphomas. Annals Of The New York Academy Of Sciences 2001, 941: 123-138. PMID: 11594566, DOI: 10.1111/j.1749-6632.2001.tb03716.x.
The Clonotypic T Cell Receptor Is a Source of Tumor‐associated Antigens in Cutaneous T Cell LymphomaBERGER C, LONGLEY J, HANLON D, GIRARDI M, EDELSON R. The Clonotypic T Cell Receptor Is a Source of Tumor‐associated Antigens in Cutaneous T Cell Lymphoma. Annals Of The New York Academy Of Sciences 2001, 941: 106-122. PMID: 11594564, DOI: 10.1111/j.1749-6632.2001.tb03715.x.
CUTANEOUS T-CELL LYMPHOMA AND CUTANEOUS GRAFT-VERSUS-HOST DISEASE Two Indications for Photopheresis in DermatologyGirardi M, Heald PW. CUTANEOUS T-CELL LYMPHOMA AND CUTANEOUS GRAFT-VERSUS-HOST DISEASE Two Indications for Photopheresis in Dermatology. Dermatologic Clinics 2000, 18: 417-423. PMID: 10943537, DOI: 10.1016/s0733-8635(05)70190-x.
Cutaneous T-cell lymphoma: pathogenesis and treatment.Girardi M, Edelson RL. Cutaneous T-cell lymphoma: pathogenesis and treatment. Oncology 2000, 14: 1061-70; discussion 1070-4, 1076. PMID: 10929591.
Postirradiation Morphea of the Breast Presentation of Two Cases and Review of the LiteratureSchaffer J, Carroll C, Dvoretsky I, Huether M, Girardi M. Postirradiation Morphea of the Breast Presentation of Two Cases and Review of the Literature. Dermatology 2000, 200: 67-71. PMID: 10681621, DOI: 10.1159/000018322.
Familial Multiple Basaloid Follicular Hamartomas: A Report of Two Affected SistersGirardi M, Federman G, McNiff J. Familial Multiple Basaloid Follicular Hamartomas: A Report of Two Affected Sisters. Pediatric Dermatology 1999, 16: 281-284. PMID: 10469412, DOI: 10.1046/j.1525-1470.1999.00061.x.
Subcutaneous Fusarium foot abscess in a renal transplant patient.Girardi M, Glusac EJ, Imaeda S. Subcutaneous Fusarium foot abscess in a renal transplant patient. Cutis 1999, 63: 267-70. PMID: 10349541.
Extracorporeal photochemotherapy in human and murine graft-versus-host diseaseGirardi M, McNiff J, Heald P. Extracorporeal photochemotherapy in human and murine graft-versus-host disease. Journal Of Dermatological Science 1999, 19: 106-113. PMID: 10098701, DOI: 10.1016/s0923-1811(98)00066-8.
Immunoprotection against tumor-specific class I-associated T lymphoma antigensBerger C, Hanlon D, Girardi M, Dong X, Yang S, Edelson R. Immunoprotection against tumor-specific class I-associated T lymphoma antigens. Journal Of Dermatological Science 1998, 16: s158. DOI: 10.1016/s0923-1811(98)83945-5.
The αβ/γδ Lineage DecisionHoffman E, Passoni L, Dudley E, Girardi M, Hayday A. The αβ/γδ Lineage Decision. 1998, 367-396. DOI: 10.1007/978-1-4757-2778-4_19.
α β and γ δ T cells can share a late common precursorDudley E, Girardi M, Owen M, Hayday A. α β and γ δ T cells can share a late common precursor. Current Biology 1995, 5: 659-669. PMID: 7552177, DOI: 10.1016/s0960-9822(95)00131-x.
Specific Suppression of Lupus-Like Graft-Versus-Host Disease Using Extracorporeal Photochemical Attenuation of Effector LymphocytesGirardi M, Herreid P, Tigelaar R. Specific Suppression of Lupus-Like Graft-Versus-Host Disease Using Extracorporeal Photochemical Attenuation of Effector Lymphocytes. Journal Of Investigative Dermatology 1995, 104: 177-182. PMID: 7829872, DOI: 10.1111/1523-1747.ep12612741.

Clinical Trials

Study Title
Molecular Markers of UV Exposure and Cancer Risk in Skin

Edit Profile

Michael Girardi, MD, FAAD

Contact Information

Mailing Address

Related Links

Patient Care

Research & Publications

Biography

News

Research Summary

Extensive Research Description

Coauthors

Research Interests

Research Images

Slide1

Science Press Girardi 2

Selected Publications

Clinical Trials